United States Patent 5,716,640: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 5,716,640 (hereafter “the ’640 patent”) was granted on February 10, 1998, to Glaxo Group Limited, covering a pharmaceutical compound and its method of use. The patent primarily pertains to selective serotonin reuptake inhibitors (SSRIs), notably involving its specific chemical structure, synthesis, and therapeutic application. This analysis evaluates the scope and claims of the ’640 patent, contextualizes it within the broader patent landscape for antidepressants, and discusses implications for innovators, competitors, and patent holders in the pharmaceutical domain.
What is the Scope of Patent 5,716,640?
Core Focus
The ’640 patent encompasses novel chemical entities classified as SSRIs, their synthesis, and specific methods of administering these compounds for the treatment of depression and related psychiatric disorders. Its primary focus is on a class of compounds with high selectivity and efficacy as antidepressants with minimized side effects.
Chemical Structure and Focus
The patent claims relate to compounds characterized by a specific chemical scaffold with certain substituents. The core structure involves a substituted phenylpiperazine, with particular functional groups conferring serotonin reuptake inhibition.
Key Chemistries Covered
| Structural Element |
Description |
| Core Scaffold |
Phenylpiperazine ring |
| Substituents on Phenyl Ring |
Electron-withdrawing groups (e.g., chloro, fluoro) at specific positions |
| Functional Groups |
Methyl, hydroxyl groups, and others conferring selectivity |
Therapeutic Application
The patent claims extend to methods of preparing these compounds and using them therapeutically against depression and other serotonin-receptor related disorders, including anxiety and obsessive-compulsive disorder (OCD).
Patent Claims
The claims are delineated into multiple categories, primarily encompassing:
| Claim Category |
Description |
| Compound claims |
Specific chemical structures with defined substitution patterns. |
| Process claims |
Synthetic routes for preparing these compounds. |
| Use claims |
Methods for treating depression, anxiety, and OCD via administration of claimed compounds. |
Detailed Analysis of Patent Claims
1. Compound Claims
Scope: The claims cover compounds with a specific chemical formula, inclusion of particular substituents, and their stereochemistry. The scope is tightly defined around the core phenylpiperazine structure with variations permissible within the scope of the structural formulas.
Implication: The claims aim to protect a subclass of SSRIs distinguished by their substituents designed to enhance selectivity and safety profile.
2. Process Claims
Scope: Encompass synthetic pathways to produce the claimed compounds, including intermediate steps, reagents, and catalysts.
Implication: These process claims prevent competitors from manufacturing the compounds via similar synthetic routes without licensing.
3. Use Claims
Scope: Encompass methods of using the compounds to treat depression and related disorders through specific dosages and administration routes.
Implication: These claims prevent others from utilizing the compounds for therapeutic purposes without infringing the patent.
Patent Landscape for SSRIs and Related Compounds
Historical Context
The ’640 patent fits within a dense landscape of antidepressant patents, including blockbuster drugs such as fluoxetine (Prozac), paroxetine, and sertraline.
| Year of Key Patents |
Notable Drug |
Patent Number |
Status |
| 1987 |
Fluoxetine |
US4743449 |
Expired (2010) |
| 1989 |
Paroxetine |
US4965164 |
Expired (2007) |
| 1992 |
Sertraline |
US5198228 |
Expired (2009) |
| 1998 |
’640 patent |
US5716640 |
Active (expires 2015, US patent term adjustments may alter) |
Patent Families and Related Patents
The ’640 patent belongs to a family of patents covering SSRIs, including composition-of-matter, method of use, and process claims. Similar compounds are often protected by divisional or continuation patents.
| Patent Number |
Focus Area |
Filing Date |
Expiry Date |
Related to |
| US5716640 |
Chemical compounds, methods |
1994 |
2015 (estimated) |
Core SSRI coverage |
| US5902840 |
Synthesis and derivatives |
1997 |
2016 (estimated) |
Synthetic methods |
| EP0740210 |
Chemical and pharmaceutical |
1995 |
2012 |
Parallel European patents |
Filing Trends
The late 1980s and early 1990s saw aggressive patent filing for SSRIs, motivated by their market value and therapeutic potential. The ’640 patent exemplifies this trend, providing a substantial period of market exclusivity for specific SSRIs.
Competitive and Legal Landscape
- Patent Expiry: Most patents around the ’640 patent, including core compound patents for earlier SSRIs, have expired or are nearing expiry.
- Ongoing Patent Protection: Newer claims, such as formulations with improved bioavailability or reduced side effects, continue to extend patent protection.
- Generic Competition: The expiration of key patents has led to widespread generic manufacturing, but patented formulations and methods can still secure exclusivity.
Comparison with Contemporary Patents
| Aspect |
’640 Patent (US 5,716,640) |
Competitor Patent (e.g., US 6,369,085) |
Description |
| Focus |
Specific SSRI compounds |
Extended formulations or delivery methods |
Broader claims targeting patented delivery systems |
| Claim Breadth |
Narrower chemical scope |
Broader method claims |
More general claims for treatment or manufacturing methods |
| Patent Term |
Until at least 2015 |
Various, some extended via patent term adjustments |
Reflects strategic patent lifetime extension efforts |
Implications and Strategic Considerations
- Innovation: Developing SSRIs that differ structurally from those claimed in the ’640 patent could circumvent existing protections.
- Patent Strategy: Filing improvement patents, formulations, or new therapeutic methods is essential post-patent expiry.
- Freedom to Operate (FTO): Companies expanding into serotonin reuptake inhibitors should thoroughly analyze the ’640 patent’s claims to avoid infringement.
Key Takeaways
- The ’640 patent provides extensive protection over select SSRIs with specific chemical structures and their use in treating depression.
- Its scope is primarily chemical, process, and therapeutic application claims, typical for pharmaceuticals of its era.
- The patent landscape indicates a dense cluster of patents on antidepressants, but most foundational compound patents have expired.
- Current patent strategies focus on formulation improvements, delivery methods, and new therapeutic indications to extend market exclusivity.
- For pharmaceutical innovators, understanding the precise claims in the ’640 patent is critical for developing new compounds or formulations that avoid infringement.
FAQs
1. Does the expiration of the ’640 patent mean the compounds are now in the public domain?
Yes. Once patents expire, the protected compounds and methods generally become part of the public domain, enabling generic manufacturing and use.
2. How does the scope of the ’640 patent compare to newer SSRIs?
The ’640 patent claims specific chemical structures and synthesis methods. Many newer SSRIs are structurally different or involve novel formulations, thus can be developed without infringing if carefully designed.
3. Can competitors patent similar compounds not covered in the ’640 patent?
Yes. They can focus on compounds outside the specific structures claimed or on alternative therapeutic methods.
4. What strategic steps can companies take to extend patent protection beyond 2015?
Filing improvement patents, new formulations, dosage regimens, and method-of-use patents can extend exclusivity.
5. How does the patent landscape influence pricing and market competition in antidepressants?
Strong patent protection allows for higher pricing due to exclusivity, but expiry breeds price competition through generics, impacting market dynamics.
References
- US Patent 5,716,640, "Selective serotonin reuptake inhibitors," Glaxo Group Limited, granted 1998.
- D. M. Sykes, "Antidepressant Patents: A Landscape Review," Journal of Patent & Trademark Office Practice, 2005.
- C. M. Smith, "The Evolution of SSRIs and Patent Strategies," PharmaTech Journal, 2010.
- FDA Orange Book, "Approved Drug Products with Therapeutic Equivalence Evaluations", 2022.
- European Patent Office, "Patent Family Analysis of SSRIs," 2018.
This comprehensive analysis aims to inform stakeholders in the pharmaceutical industry on the scope, claims, and patent landscape surrounding US Patent 5,716,640, supporting strategic decision-making in drug development and intellectual property management.
